Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
Express News | Aridis- in Discussions With Other Pharmaceutical Cos and Investment Firms on Possible Partnerships and Investments on Its Apex Platform Technology
Express News | Aridis - in Discussions With Pharmaceutical Cos,Investment Firms on Possible Partnerships on Its Clinical Product Candidates Ar- 301, Ar-320, Ar-501
Express News | Aridis Provides Corporate Update
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
Promising Developments and Value Proposition: A Buy Rating Analysis of Aridis Pharmaceuticals
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $2
Aridis Pharmaceuticals Analyst Ratings
FDA's Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals' Investment Appeal: An Analyst's Buy Recommendation
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Aridis Pharmaceuticals (ARDS.US): The 2023 Q2 financial report achieved revenue of US$19647 million, a previous value of US$292,000; earnings per share was $0.33, and a previous value of -$0.45.
Aridis Pharmaceuticals (ARDS.US): The 2023 Q2 financial report achieved revenue of US$19647 million, a previous value of US$292,000; earnings per share was $0.33, and a previous value of -$0.45.
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report on Bloomberg TV
Aridis Pharmaceuticals Announces $2 Million Offering to Fund Working Capital Needs
Aridis Pharmaceuticals Announces $2 Million Offering
12 Health Care Stocks Moving In Tuesday's After-Market Session
Sector Update: Health Care Stocks Steady Premarket Tuesday
No Data